Alnylam Pharmaceuticals said last week that the German patent office has upheld the company's Kreutzer-Limmer patent in oral proceedings held before the office's opposition board.
The patent, DE 10066235, was granted in January 2008, and covers methods, uses, and medicaments of siRNAs, with a length between 15 and 49 nucleotides, expressed through a vector, according to Alnylam.
Additionally, the patent office rejected a request by Silence Therapeutics, Pfizer, and Sanofi-Aventis, which has opposed the patent, to revoke the intellectual property, the company said.